Health Canada Issues No Objection Letter to Initiate the ELEGANSE Trial With EPX-100 to Treat Lennox-Gastaut Syndrome
16. Februar 2022 05:00 ET
|
Epygenix Therapeutics, Inc.
PARAMUS, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, Inc. ("Epygenix"), a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced...